It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyperdiploidy, i.e. gain of whole chromosomes, is one of the most common genetic features of childhood acute lymphoblastic leukemia (ALL), but its pathogenetic impact is poorly understood. Here, we report a proteogenomic analysis on matched datasets from genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of >8,000 genes and proteins as well as Hi-C of primary patient samples from hyperdiploid and ETV6/RUNX1-positive pediatric ALL. We show that CTCF and cohesin, which are master regulators of chromatin architecture, display low expression in hyperdiploid ALL. In line with this, a general genome-wide dysregulation of gene expression in relation to topologically associating domain (TAD) borders were seen in the hyperdiploid group. Furthermore, Hi-C of a limited number of hyperdiploid childhood ALL cases revealed that 2/4 cases displayed a clear loss of TAD boundary strength and 3/4 showed reduced insulation at TAD borders, with putative leukemogenic effects.
High hyperploidy is a common feature in childhood B-cell precursor acute lymphoblastic leukemia. Here, the authors perform proteogenomic and Hi-C analyses of this leukemia and the ETV6/RUNX1 subtype and show that CTCF and cohesin expression are low in hyperdiploid cases and transcriptional dysregulation in relation to topologically associating domain borders in some of these cases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
2 Science for Life Laboratory and Karolinska Institute, Clinical Proteomics Mass Spectrometry, Department of Oncology-Pathology, Stockholm, Sweden (GRID:grid.452834.c)
3 Skåne University Hospital, Lund University, Department of Pediatrics, Lund, Sweden (GRID:grid.4514.4)
4 University of Cambridge, Li Ka Shing Centre, Cancer Research UK Cambridge Institute (CRUK-CI), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Division of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
5 Lund University, Division of Clinical Genetics, Department of Laboratory Medicine, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Office for Medical Services, Division of Laboratory Medicine, Department of Clinical Genetics and Pathology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
6 University of Cambridge, Li Ka Shing Centre, Cancer Research UK Cambridge Institute (CRUK-CI), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Queen’s University Belfast, Precision Medicine Centre of Excellence, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)